Conclusion: The CAPD with low T3 syndrome is correlated PWV, and the CAPD patients with low T3 syndrome show increased arterial stiffness. Objective: To explore the influence of peritonitis on CAPD patients of gastrointestinal symptoms and gastric myoelectrical activity, and to explore the correlation between gastrointestinal symptoms and gastric myoelectrical activity. Methods: 72 patients were selected, including 24 patients with suffering peritonitis (group A), 24 patients with having suffered and cured peritonitis 3 months ago (group B), and 24 normal CAPD patients (group C) as the control group. All cases were evaluated subjectively with Gastrointestinal Symptom Rating Scale (GSRS). The gastric myoelectric activity was assessed by cutaneously recorded electrogastrographs (EGGs) in the resting state. Results: (1) The incidence of gastrointestinal symptoms in group A, group B and group C was respectively 91.67%, 70.83% and 54.17%. (2) GSRS scale scores of patients in group A in abdominal pain, dyspepsia and gastroesophageal reflux were significantly higher than that of group B and C (P < 0.01). GSRS scale scores of group B in dyspepsia, constipation, abdominal pain and eating dysfunction were higher than group C, although were no significant difference (P > 0.05). (3) The gastric electrical frequency (2.5e3.75 cpm) percentage before a meal and after standard meal in group A was significantly lower than that of group B and group C (P < 0.05), and in group C was higher than that in group B (P < 0.05). (4) The variance of EGG dominant frequency and power after a standard meal in group A and group B were less decreased, compared with the changes of group C (P < 0.05).
Background: Research indicates that the socioeconomic status (SES) of individuals and the area where they live are related to initial peritonitis and outcomes in peritoneal dialysis (PD). Therefore, a retrospective, multi-center cohort study was conducted in China to examine these associations. Methods: Data on 2,171 PD patients were collected from seven centers, including baseline demographic, socioeconomic, and laboratory data. We explored the potential risk factors for initial peritonitis and outcomes using univariate Cox regression and unadjusted binary logistic regression. Then, we used propensity score matching to balance statistically significant risk factors for initial peritonitis and outcomes, and Kaplan-Meier survival analysis to compare differences in peritonitis-free rates between different groups of participants after matching. Results: A total of 563 (25.9%) initial episodes of peritonitis occurred during the study period. The Kaplan-Meier peritonitis-free rate curve showed high-income patients had a significantly lower risk than low-income patients (p Z 0.007) after matching for age, hemoglobin, albumin, and regional SES and PD center. The risk of treatment failure was significantly lower in the high-income than the low-income group after matching for the organism causing peritonitis and PD center: OR Z 0.27 (0.09e0.80, p Z 0.018). Regional SES and education were not associated with initial peritonitis and outcomes. Conclusion: Our study demonstrates low individual income is a risk factor for the initial onset of peritonitis and treatment failure after initial peritonitis. Objective: Arcanobacterium pyogenes itself is a well-known zoonotic pathogen. Reports of human infections are rare. Here we describe a case of A. pyogenes infection by blood culture, in a hemadialysis (HD) patient with central venous catheter (CVC) without typical epidemiological exposure. Characteristics of human infection with A. pyogenes also are presented. Methods: Here we describe a case in a 54-year-old man, who depending on HD by a permanent CVC and with no identified animal contact, presented with catheter-related infection caused by Arcanobacterium pyogenes.
Results: Blood cultures from both the CVC and peripheral site were abtained. Standard biochemical bacteriological testing confirmed A. pyogenes. The patient was treated with vancomycin 0.5 g every 8 hours plus ceftizoxime 3.0 g once daily Dialysis S127
